Amicus Therapeutics has been fighting off prospective generics for Galafold®.  Teva settled with Amicus in October 2024, but Aurobindo continued to fight.  The parties recently went to trial, and on November 5, they exchanged their first round of post-trial briefing.  The briefing suggests Amicus faces risk under Section 101 for at least two of its patents as well as prior art risk on all of them.  What do the briefs say?

I have blogged about the Amgen v. Sanofi case several times, and the case has been summarized in my prior posts andelsewhere.  The case pitted two competing PCSK9-inhibitors against one another, and after several years, resulted in cancelling broad patents covering the new class of antibodies.  Whenever there is any case that cancels patents within the pharmaceutical or biotech space, the common knee-jerk retort from some commentators is that the decision will suppress innovation, chill R&D and discourage any investment in life-saving medicine.  In this case, the opposite is true.